Inhibition of [3H]dopamine uptake by platelets by the dopamine-D2 receptor agonist RU 24926.
We have examined the effect of the dopamine-D2 receptor agonist RU 24926 (N-n-propyl-di-beta(3-hydroxy-phenyl)-ethylamine HCl) on [3H]dopamine uptake by human platelets. RU 24926 reduced the uptake of [3H]dopamine by platelet-rich plasma and this affect was not reversed by the dopamine-D2 receptor antagonist haloperidol, or the dopamine-D1 receptor antagonist SCH 23390 (8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol). These data suggest that RU 24926 reduces [3H]dopamine uptake by platelets by competing for the dopamine uptake mechanism on the platelet and not by activation of the dopamine-D2 receptor.
Dean
B
B
Mental Health Research Institute of Victoria, Parkville, Australia.
Srikanthan
P
P
Copolov
D L
DL
D001552:Benzazepines / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D010627:Phenethylamines / Q000494:pharmacology*; D014316:Tritium
D001552:Benzazepines; D010627:Phenethylamines; D014316:Tritium; C025254:RU 24926; D006220:Haloperidol; D004298:Dopamine